[342 Pages Report] The globaloncology blood testingmarket size is likely to be valued at US$ 3,851.7 Mn in 2022 and is expected to reach US$ 18,278.2 Mn by 2032. The market is likely to exhibit immense growth at a CAGR of 15.2% during the forecast period.
Attributes
Details
Oncology Blood Testing Market Size (2022)
US$ 3,851.7 million
Oncology Blood Testing Market Size (2032)
US$ 18,278.2 million
Oncology Blood Testing Market CAGR
15.2%
To reduce gaps in precision medicine practice, companies provide various molecular decision support systems that amalgamate genomic and clinical data surging the demand for oncology blood testing. Researchers enabled the diagnosis of genetic mutations of distinct cancers owing to the latest research and advancements surging the adoption of oncology blood testing.
The ability to detect cancerous cells through advanced human genome sequencing expands the oncology blood testing market share. The rising number of people getting diagnosed with cancer increases expenditure on research, further propelling the oncology blood testing market size. The oncology blood testing market growth through 2031 owes to the surge in technological innovation and advancements.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
What are the Key Drivers that Expand the Oncology Blood Testing Market?
The increasing cost of development and sequencing of the Human Genome Project in the field of genomics owing to the proliferation of sequencing techniques such as NGS propels the oncology blood testing market growth.
Multiple investment programs in precision medicine by key companies drive the demand for oncology blood testing. The adoption of oncology blood testing increases with the hike in the availability of advanced molecular techniques for diagnosis.
Growing awareness about advanced treatment therapies amongst the population expands the oncology blood testing market share. Demand for oncology blood testing grows owing to favorable and uncomplicated reimbursement policies. Increasing cases of hematologic or blood cancer grow the demand for oncology blood testing.
Monitoring the status of minimal residual disease due to rising cases of myeloma cancers and lymphoma along with leukemia in patients escalates the adoption of oncology blood testing. Increasing awareness about blood cancer and its early diagnosis disseminated by government and non-government organizations boosts the oncology blood testing market share.
High prevalence and incidence of cancer, inducing a rapid surge in the burden of sample processing in healthcare facilities, bolsters the oncology blood testing market size. Cancer detection in blood via blood testing assays and kits with the capability of being an efficient diagnostic tool increases the adoption of oncology blood testing. The rising demand for preventative care and accurate diagnosis propels the adoption of oncology blood testing.
The number of cancer cases in the world in 2018 was 18.0 Mn, according to the World Health Organisation (WHO), which promises growth of the oncology blood testing market share. Various academic and research witnessing an increase in the number of research studies to develop genetic testing for various blood cancers increases demand for oncology blood testing. The oncology blood testing market size broadens owing to a rise in product approvals.
The presence of healthcare professionals to conduct diagnostic tests surged the adoption of oncology blood testing. The availability of specialized laboratory settings expands the oncology blood testing market share. The affordability of instruments used for blood cancer diagnosis assists in the growth of the oncology blood testing market size.
The effectiveness and credibility of new diagnostic methods elevate the demand for oncology blood testing. The rise in PCR-based tests to detect IDH1 genetic mutations in the bone marrow and blood samples extends the oncology blood testing market growth.
What are the Factors that Obstruct the Oncology Blood Testing Market?
Uncertain reimbursement scenarios in undeveloped regions curb the adoption of oncology blood testing. Diagnostic tools to detect cancer using blood samples, being under development and clinical trial stage, thus being unavailable commercially hinders the oncology blood testing market growth.
Lockdown restrictions due to COVID-19 disrupting the supply chain hampered the demand for oncology blood testing. High costs associated with molecular diagnostics and budgetary limitations obstruct the demand for oncology blood testing. The requirement and sporadic availability of sophisticated facilities further impede the oncology blood testing market growth.
Find your sweet spots for generating winning opportunities in this market.
What are the Possibilities that Expand the Oncology Blood Testing Market?
Improving the efficiencies and precision in cancer diagnostics and prevention via new innovative technologies like fluid biopsies, real-time cancer diagnostics, digital PCR, immunohistochemistry, next-generation sequencing (NGS), molecular testing, and cytogenetics escalates the adoption of oncology blood testing. Public and private partnerships and movements toward molecular pathology escalate the demand for oncology blood testing.
A growing number of FDA approvals for NGS-based tests in the U.S. further propels the oncology blood testing market growth. Increasing collaborations between manufacturers in the market grow the demand for oncology blood testing. Rising conferences on personalized medicines bolster the adoption of oncology blood testing.
Advancements in genetic testing generating a significant impact on diagnostic trends increase the demand for oncology blood testing. An increase in the availability of technologically advanced products for the diagnosis of acute myeloid and leukemia progresses the oncology blood testing market share.
An increase in the co-development of the drug-diagnostics model further expands the oncology blood testing market size. A greater understanding of diagnostic procedures and the availability of technologically advanced products for diagnosis grows the demand for oncology blood testing. Growth in the expenditure and implementation of R&D activities further expand the oncology blood testing market size.
Regional Analysis
How is the Performance of the North America Oncology Blood Testing Market?
North America dominates the oncology blood testing market share with a revenue of 52.6% in 2022.
This is owing to favourable reimbursement policies and increase in cancer cases amongst the population, along with the awareness on early diagnosis of cancer. This region necessitates the demand for oncology blood testing and advanced technologies to prevent, diagnose and treat cancer.
The growth of the market is further attributed to the rising cases of leukaemia, lymphoma, and multiple myeloma. The survival rate for the disease is approximated to be 86.6% due to the timely diagnosis and emergence of novel therapies.
What is the Growth Outlook for the Europe Oncology Blood Testing Market?
Europe registers the second largest oncology blood testing market share with a revenue of 30.6% in 2022.
Owing to easy regulatory approval for in-vitro cancer diagnostics, the Europe oncology blood testing market promises growth. The interesting incidence of multiple myeloma across Europe, further fuels the oncology blood testing market growth.
How will the Asia Pacific Oncology Blood Testing Market Grow?
The Asia Pacific is expected to grow in the global oncology blood testing market share.
Growth in the prevalence of blood cancer in several countries of this region.
Increasing number of research activities regulated by various academic research academies further propels the global market growth.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Startup Ecosystem
How is the Start-up Ecosystem in the Oncology Blood Testing Market?
Changes in the market and the advent of new technologies contributing to the research and development of new diagnostic tools that aid in the treatment and prevention of cancer are gaining significant popularity.
The awareness of early diagnosis and an interesting number of cancer patients throughout the world surges the perpetual research work against the constant emergence of this fatal illness.
Certain start-up companies are contributing to the overall market growth by devising strategies to counteract blood cancer in the population.
Adaptive Biotechnologies, Grail, Abingdon Health, Freenome, Vivia Biotech, Genoptix, Biofluidica, SkylineDX, etc. provide clinical diagnostics, gene expression profiling tests for personalized medicine, liquid biopsy tests using CTCs, and help scientists and clinicians in research and drug development.
What is the Competitive Landscape of the Oncology Blood Testing Market?
Some of the key market participants in the oncology blood testing market are Guardant Health Inc., Trovagene Inc., Genomic Health Inc., Foundation Medicine Inc., Exosome Diagnostics, Pathway Genomics Corporation, F. Hoffman-La Roche Ltd., Abbott Laboratories, EntroGen Inc., Qiagen N.V., Cepheid, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Illumina Inc., CORE Diagnostics, Genoptix Inc., GenPath, NeoGenomics Laboratories Inc., Siemens, MolecularMD, ArcherDx Inc., ARUP Laboratories., Invivoscribe Inc., GenPath, Laboratory Corporation of America Holdings, Luminex Corporation, Myriad Genetics Inc., Roche Holding A.G., Invitae Corporation, Asuragen Inc., Molecularmd, EntroGen, Cepheid, Cancer Genetics, Adaptive Biotechnologies, Grail, Abingdon Health, Freenome, Vivia Biotech, Biofluidica, SkylineDX, Biodesix Inc., NovellusDX, BioNTech SE, etc.
They aim to research and develop diagnostic tools that aid in early detection of cancer in patients. Using liquid biopsies to detect the life threatening disease and try and combat it in time, is the utmost goal of healthcare centers – with the assistance of these key players, the healthcare sector is improving in this arena.
Some of the recent developments in the oncology blood testing market are:
In August 2019, a novel blood test that helps in the detection of myeloma was developed by scientists from Monash University.
In October 2018, the launch of a screening study for individuals who are at high risk of multiple myeloma was announced by scientists from Dana-Farber Cancer Institute.
In 2018, a research study conducted by Bloodwise - a blood cancer research charity team, indicating positive results for the research study, expected to facilitate the use of personalised medicine for the treatment of Acute Myeloid Lukemia (AML).
In May 2021, the launch of the first blood-based pan-cancer study in China was achieved by Burning Rock Biotech Limited, based on a multi-omics approach.
In July 2021, the opening of the headquarters of Biofidelity Ltd. - a renowned name in cancer diagnostics, in North Carolina, the U.S. was announced.
Scope of Report
Report Attribute
Details
Growth Rate
CAGR of 15.2% from 2022 to 2032
Base year for estimation
2021
Historical data
2016 - 2021
Forecast period
2022 - 2032
Quantitative units
Revenue in USD million and CAGR from 2022 to 2032
Report coverage
Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis,
Segments covered
Types, Application, End User, and Region.
Regional scope
North America; Western Europe, Eastern Europe, Middle East, Africa, ASEAN, South Asia, Rest of Asia, Australia and New Zealand
Country scope
USA; Canada; Mexico; Germany; UK; France; Italy; Spain; Russia; Belgium; Poland; Czech Republic; China; India; Japan; Australia; Brazil; Argentina; Colombia; Saudi Arabia; UAE; Iran; South Africa
Key companies profiled
Guardant Health Inc., Trovagene Inc., Genomic Health Inc., Foundation Medicine Inc., Exosome Diagnostics, Pathway Genomics Corporation, F. Hoffman-La Roche Ltd., Abbott Laboratories, EntroGen Inc., Qiagen N.V., Cepheid, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Illumina Inc., CORE Diagnostics, Genoptix Inc., GenPath, NeoGenomics Laboratories Inc., Siemens, MolecularMD, ArcherDx Inc., ARUP Laboratories., Invivoscribe Inc., GenPath, Laboratory Corporation of America Holdings, Luminex Corporation, Myriad Genetics Inc., Roche Holding A.G., Invitae Corporation, Asuragen Inc., Molecularmd, EntroGen, Cepheid, Cancer Genetics, Adaptive Biotechnologies, Grail, Abingdon Health, Freenome, Vivia Biotech, Biofluidica, SkylineDX, Biodesix Inc., NovellusDX, BioNTech SE, etc.
Customization scope
Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs.
Frequently Asked Questions
How much CAGR can be Estimated for the Oncology Blood Testing Market?
The oncology blood testing market is likely to generate a CAGR of 15.2% during the forecast period.
What is the Leading Regional Market of Oncology Blood Testing?
North America is the leading oncology blood testing market.
What will be the Size of the Oncology Blood Testing Market by 2032?
By 2032, the oncology blood testing market is likely to grow to a valuation of US$ 18,278.2 Mn.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Oncology Blood Testing Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Oncology Blood Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Test Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Test Type, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Test Type, 2022-2032
5.3.1. CBC (Complete Blood Count) Test
5.3.2. Blood Protein Test
5.3.3. Tumor Marker Test
5.3.4. CTC (Circulating Tumor Cells) – based Test
5.3.5. NIPT (Non-Invasive Prenatal Testing) Test
5.3.6. Liquid Biopsy Assays
5.3.7. Exom-Based Liquid Biopsy
5.4. Y-o-Y Growth Trend Analysis By Test Type, 2017-2021
5.5. Absolute $ Opportunity Analysis By Test Type, 2022-2032
6. Global Oncology Blood Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Application
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Application, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Application, 2022-2032
6.3.1. Lung Cancer
6.3.2. Breast Cancer
6.3.3. Colon Cancer
6.3.4. Melanoma
6.3.5. Ovarian Cancer
6.3.6. Gastro-Intestinal Stromal Tumor (GIST)
6.4. Y-o-Y Growth Trend Analysis By Application, 2017-2021
6.5. Absolute $ Opportunity Analysis By Application, 2022-2032
7. Global Oncology Blood Testing Market Analysis 2017-2021 and Forecast 2022-2032, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Mn) Analysis By End User, 2017-2021
7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End User, 2022-2032
7.3.1. Hospitals
7.3.2. Specialty Clinics
7.3.3. Diagnostic Laboratories
7.4. Y-o-Y Growth Trend Analysis By End User, 2017-2021
7.5. Absolute $ Opportunity Analysis By End User, 2022-2032
8. Global Oncology Blood Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021
8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Oncology Blood Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. US
9.2.1.2. Canada
9.2.2. By Test Type
9.2.3. By Application
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Test Type
9.3.3. By Application
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Oncology Blood Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Test Type
10.2.3. By Application
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Test Type
10.3.3. By Application
10.3.4. By End User
10.4. Key Takeaways
11. Europe Oncology Blood Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. U.K.
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Test Type
11.2.3. By Application
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Test Type
11.3.3. By Application
11.3.4. By End User
11.4. Key Takeaways
12. Asia Pacific Oncology Blood Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.1.4. Rest of Asia Pacific
12.2.2. By Test Type
12.2.3. By Application
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Test Type
12.3.3. By Application
12.3.4. By End User
12.4. Key Takeaways
13. MEA Oncology Blood Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of MEA
13.2.2. By Test Type
13.2.3. By Application
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Test Type
13.3.3. By Application
13.3.4. By End User
13.4. Key Takeaways
14. Key Countries Oncology Blood Testing Market Analysis
14.1. US
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2021
14.1.2.1. By Test Type
14.1.2.2. By Application
14.1.2.3. By End User
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2021
14.2.2.1. By Test Type
14.2.2.2. By Application
14.2.2.3. By End User
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2021
14.3.2.1. By Test Type
14.3.2.2. By Application
14.3.2.3. By End User
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2021
14.4.2.1. By Test Type
14.4.2.2. By Application
14.4.2.3. By End User
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2021
14.5.2.1. By Test Type
14.5.2.2. By Application
14.5.2.3. By End User
14.6. U.K.
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2021
14.6.2.1. By Test Type
14.6.2.2. By Application
14.6.2.3. By End User
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2021
14.7.2.1. By Test Type
14.7.2.2. By Application
14.7.2.3. By End User
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2021
14.8.2.1. By Test Type
14.8.2.2. By Application
14.8.2.3. By End User
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2021
14.9.2.1. By Test Type
14.9.2.2. By Application
14.9.2.3. By End User
14.10. China
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2021
14.10.2.1. By Test Type
14.10.2.2. By Application
14.10.2.3. By End User
14.11. Japan
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2021
14.11.2.1. By Test Type
14.11.2.2. By Application
14.11.2.3. By End User
14.12. South Korea
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2021
14.12.2.1. By Test Type
14.12.2.2. By Application
14.12.2.3. By End User
14.13. GCC Countries
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2021
14.13.2.1. By Test Type
14.13.2.2. By Application
14.13.2.3. By End User
14.14. South Africa
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2021
14.14.2.1. By Test Type
14.14.2.2. By Application
14.14.2.3. By End User
14.15. Israel
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2021
14.15.2.1. By Test Type
14.15.2.2. By Application
14.15.2.3. By End User
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Test Type
15.3.3. By Application
15.3.4. By End User
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Guardant Health Inc.
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. Multigen Diagnostics
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. Genomic Health Inc.
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. Foundation Medicine Inc.
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Exosome Diagnostics
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. Roche
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. Bio-Techne
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
17. Assumptions & Acronyms Used18. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Oncology Blood Testing Market Value (US$ Mn) Forecast by Region, 2017-2032
Table 2: Global Oncology Blood Testing Market Value (US$ Mn) Forecast by Test Type, 2017-2032
Table 3: Global Oncology Blood Testing Market Value (US$ Mn) Forecast by Application, 2017-2032
Table 4: Global Oncology Blood Testing Market Value (US$ Mn) Forecast by End User, 2017-2032
Table 5: North America Oncology Blood Testing Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 6: North America Oncology Blood Testing Market Value (US$ Mn) Forecast by Test Type, 2017-2032
Table 7: North America Oncology Blood Testing Market Value (US$ Mn) Forecast by Application, 2017-2032
Table 8: North America Oncology Blood Testing Market Value (US$ Mn) Forecast by End User, 2017-2032
Table 9: Latin America Oncology Blood Testing Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 10: Latin America Oncology Blood Testing Market Value (US$ Mn) Forecast by Test Type, 2017-2032
Table 11: Latin America Oncology Blood Testing Market Value (US$ Mn) Forecast by Application, 2017-2032
Table 12: Latin America Oncology Blood Testing Market Value (US$ Mn) Forecast by End User, 2017-2032
Table 13: Europe Oncology Blood Testing Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 14: Europe Oncology Blood Testing Market Value (US$ Mn) Forecast by Test Type, 2017-2032
Table 15: Europe Oncology Blood Testing Market Value (US$ Mn) Forecast by Application, 2017-2032
Table 16: Europe Oncology Blood Testing Market Value (US$ Mn) Forecast by End User, 2017-2032
Table 17: Asia Pacific Oncology Blood Testing Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 18: Asia Pacific Oncology Blood Testing Market Value (US$ Mn) Forecast by Test Type, 2017-2032
Table 19: Asia Pacific Oncology Blood Testing Market Value (US$ Mn) Forecast by Application, 2017-2032
Table 20: Asia Pacific Oncology Blood Testing Market Value (US$ Mn) Forecast by End User, 2017-2032
Table 21: MEA Oncology Blood Testing Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 22: MEA Oncology Blood Testing Market Value (US$ Mn) Forecast by Test Type, 2017-2032
Table 23: MEA Oncology Blood Testing Market Value (US$ Mn) Forecast by Application, 2017-2032
Table 24: MEA Oncology Blood Testing Market Value (US$ Mn) Forecast by End User, 2017-2032
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Oncology Blood Testing Market Value (US$ Mn) by Test Type, 2022-2032
Figure 2: Global Oncology Blood Testing Market Value (US$ Mn) by Application, 2022-2032
Figure 3: Global Oncology Blood Testing Market Value (US$ Mn) by End User, 2022-2032
Figure 4: Global Oncology Blood Testing Market Value (US$ Mn) by Region, 2022-2032
Figure 5: Global Oncology Blood Testing Market Value (US$ Mn) Analysis by Region, 2017-2032
Figure 6: Global Oncology Blood Testing Market Value Share (%) and BPS Analysis by Region, 2022-2032
Figure 7: Global Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Region, 2022-2032
Figure 8: Global Oncology Blood Testing Market Value (US$ Mn) Analysis by Test Type, 2017-2032
Figure 9: Global Oncology Blood Testing Market Value Share (%) and BPS Analysis by Test Type, 2022-2032
Figure 10: Global Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Test Type, 2022-2032
Figure 11: Global Oncology Blood Testing Market Value (US$ Mn) Analysis by Application, 2017-2032
Figure 12: Global Oncology Blood Testing Market Value Share (%) and BPS Analysis by Application, 2022-2032
Figure 13: Global Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Application, 2022-2032
Figure 14: Global Oncology Blood Testing Market Value (US$ Mn) Analysis by End User, 2017-2032
Figure 15: Global Oncology Blood Testing Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 16: Global Oncology Blood Testing Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 17: Global Oncology Blood Testing Market Attractiveness by Test Type, 2022-2032
Figure 18: Global Oncology Blood Testing Market Attractiveness by Application, 2022-2032
Figure 19: Global Oncology Blood Testing Market Attractiveness by End User, 2022-2032
Figure 20: Global Oncology Blood Testing Market Attractiveness by Region, 2022-2032
Figure 21: North America Oncology Blood Testing Market Value (US$ Mn) by Test Type, 2022-2032
Figure 22: North America Oncology Blood Testing Market Value (US$ Mn) by Application, 2022-2032
Figure 23: North America Oncology Blood Testing Market Value (US$ Mn) by End User, 2022-2032
Figure 24: North America Oncology Blood Testing Market Value (US$ Mn) by Country, 2022-2032
Figure 25: North America Oncology Blood Testing Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 26: North America Oncology Blood Testing Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 27: North America Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 28: North America Oncology Blood Testing Market Value (US$ Mn) Analysis by Test Type, 2017-2032
Figure 29: North America Oncology Blood Testing Market Value Share (%) and BPS Analysis by Test Type, 2022-2032
Figure 30: North America Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Test Type, 2022-2032
Figure 31: North America Oncology Blood Testing Market Value (US$ Mn) Analysis by Application, 2017-2032
Figure 32: North America Oncology Blood Testing Market Value Share (%) and BPS Analysis by Application, 2022-2032
Figure 33: North America Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Application, 2022-2032
Figure 34: North America Oncology Blood Testing Market Value (US$ Mn) Analysis by End User, 2017-2032
Figure 35: North America Oncology Blood Testing Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 36: North America Oncology Blood Testing Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 37: North America Oncology Blood Testing Market Attractiveness by Test Type, 2022-2032
Figure 38: North America Oncology Blood Testing Market Attractiveness by Application, 2022-2032
Figure 39: North America Oncology Blood Testing Market Attractiveness by End User, 2022-2032
Figure 40: North America Oncology Blood Testing Market Attractiveness by Country, 2022-2032
Figure 41: Latin America Oncology Blood Testing Market Value (US$ Mn) by Test Type, 2022-2032
Figure 42: Latin America Oncology Blood Testing Market Value (US$ Mn) by Application, 2022-2032
Figure 43: Latin America Oncology Blood Testing Market Value (US$ Mn) by End User, 2022-2032
Figure 44: Latin America Oncology Blood Testing Market Value (US$ Mn) by Country, 2022-2032
Figure 45: Latin America Oncology Blood Testing Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 46: Latin America Oncology Blood Testing Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 47: Latin America Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 48: Latin America Oncology Blood Testing Market Value (US$ Mn) Analysis by Test Type, 2017-2032
Figure 49: Latin America Oncology Blood Testing Market Value Share (%) and BPS Analysis by Test Type, 2022-2032
Figure 50: Latin America Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Test Type, 2022-2032
Figure 51: Latin America Oncology Blood Testing Market Value (US$ Mn) Analysis by Application, 2017-2032
Figure 52: Latin America Oncology Blood Testing Market Value Share (%) and BPS Analysis by Application, 2022-2032
Figure 53: Latin America Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Application, 2022-2032
Figure 54: Latin America Oncology Blood Testing Market Value (US$ Mn) Analysis by End User, 2017-2032
Figure 55: Latin America Oncology Blood Testing Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 56: Latin America Oncology Blood Testing Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 57: Latin America Oncology Blood Testing Market Attractiveness by Test Type, 2022-2032
Figure 58: Latin America Oncology Blood Testing Market Attractiveness by Application, 2022-2032
Figure 59: Latin America Oncology Blood Testing Market Attractiveness by End User, 2022-2032
Figure 60: Latin America Oncology Blood Testing Market Attractiveness by Country, 2022-2032
Figure 61: Europe Oncology Blood Testing Market Value (US$ Mn) by Test Type, 2022-2032
Figure 62: Europe Oncology Blood Testing Market Value (US$ Mn) by Application, 2022-2032
Figure 63: Europe Oncology Blood Testing Market Value (US$ Mn) by End User, 2022-2032
Figure 64: Europe Oncology Blood Testing Market Value (US$ Mn) by Country, 2022-2032
Figure 65: Europe Oncology Blood Testing Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 66: Europe Oncology Blood Testing Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 67: Europe Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 68: Europe Oncology Blood Testing Market Value (US$ Mn) Analysis by Test Type, 2017-2032
Figure 69: Europe Oncology Blood Testing Market Value Share (%) and BPS Analysis by Test Type, 2022-2032
Figure 70: Europe Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Test Type, 2022-2032
Figure 71: Europe Oncology Blood Testing Market Value (US$ Mn) Analysis by Application, 2017-2032
Figure 72: Europe Oncology Blood Testing Market Value Share (%) and BPS Analysis by Application, 2022-2032
Figure 73: Europe Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Application, 2022-2032
Figure 74: Europe Oncology Blood Testing Market Value (US$ Mn) Analysis by End User, 2017-2032
Figure 75: Europe Oncology Blood Testing Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 76: Europe Oncology Blood Testing Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 77: Europe Oncology Blood Testing Market Attractiveness by Test Type, 2022-2032
Figure 78: Europe Oncology Blood Testing Market Attractiveness by Application, 2022-2032
Figure 79: Europe Oncology Blood Testing Market Attractiveness by End User, 2022-2032
Figure 80: Europe Oncology Blood Testing Market Attractiveness by Country, 2022-2032
Figure 81: Asia Pacific Oncology Blood Testing Market Value (US$ Mn) by Test Type, 2022-2032
Figure 82: Asia Pacific Oncology Blood Testing Market Value (US$ Mn) by Application, 2022-2032
Figure 83: Asia Pacific Oncology Blood Testing Market Value (US$ Mn) by End User, 2022-2032
Figure 84: Asia Pacific Oncology Blood Testing Market Value (US$ Mn) by Country, 2022-2032
Figure 85: Asia Pacific Oncology Blood Testing Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 86: Asia Pacific Oncology Blood Testing Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 87: Asia Pacific Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 88: Asia Pacific Oncology Blood Testing Market Value (US$ Mn) Analysis by Test Type, 2017-2032
Figure 89: Asia Pacific Oncology Blood Testing Market Value Share (%) and BPS Analysis by Test Type, 2022-2032
Figure 90: Asia Pacific Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Test Type, 2022-2032
Figure 91: Asia Pacific Oncology Blood Testing Market Value (US$ Mn) Analysis by Application, 2017-2032
Figure 92: Asia Pacific Oncology Blood Testing Market Value Share (%) and BPS Analysis by Application, 2022-2032
Figure 93: Asia Pacific Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Application, 2022-2032
Figure 94: Asia Pacific Oncology Blood Testing Market Value (US$ Mn) Analysis by End User, 2017-2032
Figure 95: Asia Pacific Oncology Blood Testing Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 96: Asia Pacific Oncology Blood Testing Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 97: Asia Pacific Oncology Blood Testing Market Attractiveness by Test Type, 2022-2032
Figure 98: Asia Pacific Oncology Blood Testing Market Attractiveness by Application, 2022-2032
Figure 99: Asia Pacific Oncology Blood Testing Market Attractiveness by End User, 2022-2032
Figure 100: Asia Pacific Oncology Blood Testing Market Attractiveness by Country, 2022-2032
Figure 101: MEA Oncology Blood Testing Market Value (US$ Mn) by Test Type, 2022-2032
Figure 102: MEA Oncology Blood Testing Market Value (US$ Mn) by Application, 2022-2032
Figure 103: MEA Oncology Blood Testing Market Value (US$ Mn) by End User, 2022-2032
Figure 104: MEA Oncology Blood Testing Market Value (US$ Mn) by Country, 2022-2032
Figure 105: MEA Oncology Blood Testing Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 106: MEA Oncology Blood Testing Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 107: MEA Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 108: MEA Oncology Blood Testing Market Value (US$ Mn) Analysis by Test Type, 2017-2032
Figure 109: MEA Oncology Blood Testing Market Value Share (%) and BPS Analysis by Test Type, 2022-2032
Figure 110: MEA Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Test Type, 2022-2032
Figure 111: MEA Oncology Blood Testing Market Value (US$ Mn) Analysis by Application, 2017-2032
Figure 112: MEA Oncology Blood Testing Market Value Share (%) and BPS Analysis by Application, 2022-2032
Figure 113: MEA Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Application, 2022-2032
Figure 114: MEA Oncology Blood Testing Market Value (US$ Mn) Analysis by End User, 2017-2032
Figure 115: MEA Oncology Blood Testing Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 116: MEA Oncology Blood Testing Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 117: MEA Oncology Blood Testing Market Attractiveness by Test Type, 2022-2032
Figure 118: MEA Oncology Blood Testing Market Attractiveness by Application, 2022-2032
Figure 119: MEA Oncology Blood Testing Market Attractiveness by End User, 2022-2032
Figure 120: MEA Oncology Blood Testing Market Attractiveness by Country, 2022-2032
